Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

What is TB 500? A 2026 Deep Dive on Thymosin Beta-4

In the relentless pace of 2026, the demand for more efficient, more profound methods of recovery and cellular repair has never been greater. Whether it's in high-level athletics, demanding professional fields, or cutting-edge biomedical research, the ability t

By Recovery & Performance Peptides Editorial Team

In the relentless pace of 2026, the demand for more efficient, more profound methods of recovery and cellular repair has never been greater. Whether it's in high-level athletics, demanding professional fields, or cutting-edge biomedical research, the ability to bounce back from injury and stress is a critical, non-negotiable element of success. It's a universal challenge. This is precisely where the scientific community's interest has pivoted towards novel compounds, and one name consistently surfaces in these conversations: TB-500. So, the central question we hear from labs and researchers every day is, what is TB 500?

It’s a question that cuts through the noise of countless supplements and therapies. Here at Real Peptides, our team has spent years focused on providing the highest-purity compounds for research, and we've seen firsthand the burgeoning interest in peptides that target the body's own regenerative systems. Understanding what is TB 500 is more than just learning about another molecule; it’s about grasping a fundamental shift in how we approach healing and recovery at a cellular level. It’s a fascinating, sprawling topic, and we're here to unpack it with the depth and clarity it deserves, drawing from our extensive experience in the field.

So, What Is TB 500, Really?

Let’s get straight to it. At its core, TB-500 is a synthetic fragment of a naturally occurring protein called Thymosin Beta-4 (Tβ4). Think of Tβ4 as one of the body’s master regulators for healing. It’s found in virtually all human and animal cells, with particularly high concentrations at sites of injury. It’s the microscopic first responder. When you get a cut or pull a muscle, Tβ4 is there, orchestrating the complex dance of cellular repair. To fully answer what is TB 500, you have to appreciate this origin story. The synthetic peptide, TB-500, essentially captures the most biologically active region of this larger protein. It’s a targeted, potent piece of the whole puzzle.

Why not just use the entire Tβ4 protein? It comes down to efficiency and specificity. By synthesizing this specific 43-amino-acid-long fragment, researchers can work with a molecule that delivers the primary benefits of Tβ4 in a more stable and direct manner. Our experience shows that this precision is what makes compounds like our own TB-500 (thymosin Beta-4) so valuable for controlled, repeatable studies. It removes some of the variables. The ongoing research helps scientists understand what is TB 500's role in accelerating the body’s innate healing processes, from reducing inflammation to promoting the growth of new tissue. It's not about introducing something foreign; it's about amplifying a system that's already there.

This is a critical distinction. Many approaches to recovery involve masking symptoms, but the research around TB-500 is focused on addressing the root cause. This peptide's primary function is to upregulate crucial proteins involved in cell building. That's the key. By understanding this, the question of what is TB 500 evolves from a simple definition to an appreciation of its potential to fundamentally support systemic repair. It’s a tool for investigating how to make the body better at healing itself.

The Core Mechanism: How Does It Work?

Now, this is where it gets interesting. The primary way TB-500 exerts its effects is by upregulating a protein called actin. If you’re not a cell biologist, that might not mean much, but stick with us. It’s incredibly important. Actin is a foundational building block within every cell. It forms microfilaments that are essential for cell structure, movement, division, and integrity. Think of it as the cellular scaffolding and transportation network all rolled into one. When you wonder what is TB 500 doing on a microscopic level, the answer almost always comes back to actin.

By promoting actin production, TB-500 helps cells migrate and proliferate more effectively. This is the magic behind its regenerative capabilities. When tissue is damaged, cells need to move to the injury site to begin repairs. TB-500 essentially greases the wheels for this process. This leads to faster wound healing, quicker repair of torn muscles or strained ligaments, and a more robust cellular response to trauma. It’s comprehensive. The query of what is TB 500 is really a query about enhancing cellular mobility for repair.

But that’s not all. Our team has found that its influence is far more nuanced. TB-500 also has potent anti-inflammatory properties. It helps downregulate inflammatory cytokines, which are the signaling molecules that can cause pain, swelling, and chronic inflammation when they run rampant. This dual action is what makes it so compelling for researchers. It doesn't just help rebuild; it also helps create a better environment for rebuilding to occur. Furthermore, it promotes angiogenesis—the formation of new blood vessels. More blood vessels mean more oxygen and nutrients can get to the damaged tissue, dramatically speeding up recovery. It's a multi-pronged approach to healing, and it's central to understanding what is TB 500 and its systemic effects.

TB-500 vs. BPC-157: A Common Point of Confusion

In the world of Performance & Recovery Research, another name comes up constantly: BPC-157. Researchers often ask us to clarify the difference, as both are renowned for their healing properties. Let's be honest, this is crucial. While they share a common goal of regeneration, their mechanisms and ideal applications are quite distinct. Knowing the difference is key to designing effective research protocols.

BPC-157, which we also supply with impeccable purity as BPC-157 10mg, is often described as a localized healer. It’s derived from a protein found in gastric juice and has a remarkable ability to repair tissue where it's administered, showing profound effects on gut health, tendons, and ligaments. It’s a site-specific powerhouse. TB-500, on the other hand, is a systemic agent. It travels throughout the body to find areas of injury and inflammation, promoting healing on a much broader scale. Answering what is TB 500 often involves contrasting it with BPC-157 to highlight its systemic nature.

Because of their complementary actions, many advanced research protocols study them in tandem. It's a strategy we've seen yield fascinating results in preclinical studies, which is why we've made comprehensive solutions like the Healing & Total Recovery Bundle available for the research community. This approach leverages the localized power of BPC-157 with the systemic, anti-inflammatory prowess of TB-500.

Here's a simple breakdown our team put together to clarify the key differences:

Primary Mechanism

Upregulates actin, promotes cell migration and angiogenesis.

Activates the VEGFR2 pathway, promotes tendon fibroblast growth.

Scope of Action

Systemic. Works throughout the entire body to find and repair injury.

Localized. Primarily works at or near the site of administration.

Key Research Areas

Muscle repair, soft tissue injury, inflammation reduction, heart health, neurogenesis.

Gut health, tendon/ligament repair, ulcer healing, site-specific injuries.

Source

Synthetic fragment of a naturally occurring protein (Thymosin Beta-4).

Synthetic peptide derived from a stomach protein.

Synergy

Often studied alongside BPC-157 for a comprehensive, systemic and local approach.

Excellent synergy with TB-500; they complement each other's actions.

This table helps clarify the unique roles each peptide plays. Understanding these nuances is fundamental for anyone seriously investigating what is TB 500 and how it fits into the broader landscape of regenerative peptides.

Key Areas of Research in 2026

As of 2026, the research into TB-500 has expanded far beyond its initial focus on athletic recovery. It’s a testament to the compound's versatility. The more scientists learn about what is TB 500 is capable of, the more doors open to new and exciting fields of study.

One of the most promising frontiers is in cardioprotective effects. Preclinical models have shown that TB-500 can help repair and regenerate heart tissue after an ischemic event (like a heart attack). By promoting angiogenesis and cell survival, it offers a potential avenue for mitigating the catastrophic damage such events can cause. This research is still developing, but it represents a significant, sometimes dramatic shift in focus.

Another burgeoning area is neurogenesis and brain health. Studies are exploring its potential to aid recovery from traumatic brain injuries (TBI) and other neurological insults. The ability to reduce inflammation in the brain while promoting the repair of damaged neurons is a formidable combination. This aligns with the work being done in our Cognitive & Nootropic Research category, where researchers are constantly seeking compounds that support brain plasticity and repair. The question what is TB 500's role in the brain is one of the most exciting questions being asked today.

Of course, its foundational application in soft tissue repair remains a cornerstone of its research. From nagging tendonitis to acute muscle tears, TB-500's ability to accelerate healing is well-documented in animal studies. This is its bread and butter. We've also seen a surprising amount of interest from researchers in the Hair & Skin Research field. Some studies suggest that by improving blood flow and reducing inflammation in the scalp, TB-500 may promote the reactivation of dormant hair follicles. It’s an unexpected but logical extension of its primary mechanism.

Important Considerations for Laboratory Research

Embarking on research with any peptide requires impeccable attention to detail. This is where we, as a company, place our entire focus. The integrity of your results depends entirely on the quality of the compounds you use. We can't stress this enough.

First and foremost is purity and sourcing. The peptide market is, frankly, flooded with low-quality products. Contaminants, incorrect sequences, or low purity levels can completely invalidate your research and lead to misleading results. This is why at Real Peptides, every batch of our TB-500 (thymosin Beta-4) undergoes rigorous third-party testing to guarantee its identity, purity, and concentration. When you're trying to determine what is TB 500's true effect, you can't have any confounding variables from a subpar product. It’s a non-starter.

Next comes reconstitution and storage. Peptides like TB-500 are delivered as a lyophilized (freeze-dried) powder to ensure stability during shipping. To be used in research, they must be carefully reconstituted with a sterile solvent. Our team always recommends using high-quality Bacteriostatic Reconstitution Water (bac), which contains a small amount of benzyl alcohol to prevent bacterial growth. Once reconstituted, the peptide is no longer shelf-stable and must be refrigerated to maintain its integrity. Proper handling isn't just a best practice; it's a mandatory requirement for valid scientific inquiry.

Finally, when it comes to protocols and administration in a research setting, it's vital to consult existing scientific literature. While we cannot provide dosing advice for obvious reasons, published studies on animal models typically describe a 'loading phase' followed by a 'maintenance phase.' The loading phase involves more frequent administration to quickly raise systemic levels of the peptide, while the maintenance phase uses less frequent administration to sustain those levels. Understanding these established research models is part of the due diligence required to properly investigate what is TB 500.

The Bigger Picture: Systemic Healing in a Demanding World

The exploration of what is TB 500 is more than an academic exercise. It reflects a deeper search for ways to enhance the body's own incredible capacity for self-repair. We live in a world that places grueling demands on our physical and mental resilience. The insights gained from studying compounds like TB-500 could, in the future, inform entirely new therapeutic strategies for a wide range of conditions, from chronic injuries to age-related decline.

It represents a move away from simply managing symptoms and toward fostering true, systemic regeneration. It’s about working with the body, not against it. As research continues to evolve in 2026 and beyond, peptides will undoubtedly play an even larger role in the fields of medicine, longevity, and human performance. We're proud to be at the forefront of this movement, providing the essential, high-purity tools that scientists need to push the boundaries of what's possible. We encourage you to Explore High-Purity Research Peptides and see the difference that uncompromising quality makes in yielding clear, reliable data.

The journey to fully understand the potential locked within molecules like Thymosin Beta-4 is ongoing, but it's one of the most exciting stories in modern biotechnology. Every study, every data point, and every carefully controlled experiment brings us one step closer. By continuing to ask the right questions—starting with the fundamental one, what is TB 500?—the research community is paving the way for a future where recovery is not just possible, but optimized.

Frequently Asked Questions

TB-500 is the synthetic version of the most active fragment of the naturally occurring Thymosin Beta-4 (Tβ4) protein. While Tβ4 is the full, endogenous protein, TB-500 is a peptide containing 43 amino acids that represents its primary healing and regenerative domain, making it more stable and specific for research.

No, they are different peptides with different functions. TB-500 is focused on cellular repair, actin upregulation, and inflammation reduction. Thymalin, on the other hand, is a peptide primarily associated with regulating the thymus gland and supporting immune system function.

Before reconstitution, lyophilized (freeze-dried) TB-500 should be stored in a cool, dark place, like a refrigerator. After being reconstituted with bacteriostatic water, it must be kept refrigerated at all times and is typically stable for several weeks.

Systemic action means the peptide works throughout the entire body rather than just at a specific site. After administration in a research setting, TB-500 circulates and can locate and act on various areas of injury or inflammation, which is a key part of answering what is TB 500’s primary benefit.

Yes, many research protocols investigate the synergistic effects of combining TB-500 and BPC-157. BPC-157 provides powerful localized healing, while TB-500 offers systemic repair and anti-inflammatory benefits, creating a comprehensive model for study.

Actin is a critical protein that forms the structural filaments inside cells, essential for cell movement, division, and integrity. TB-500’s primary mechanism is upregulating actin, which allows cells to migrate to injury sites more efficiently to begin the repair process.

Current research is exploring a wide range of applications beyond soft tissue repair. Key areas in 2026 include its cardioprotective effects after heart injury, its potential for neurogenesis and TBI recovery, and even its role in hair and skin health.

Purity is paramount because impurities or incorrect peptide sequences can produce misleading or invalid results, completely compromising a study. Our team at Real Peptides guarantees purity through third-party testing to ensure researchers are working with the exact molecule they intend to study.

Yes, this is a significant aspect of its function. TB-500 has been shown in studies to downregulate inflammatory cytokines, which helps reduce swelling and pain, creating a more favorable environment for tissue to heal and regenerate.

For proper lab use, you will need the lyophilized TB-500 peptide, a vial of sterile bacteriostatic water for reconstitution, and sterile syringes for accurately measuring and transferring the liquids. Proper cold storage, like a refrigerator, is also essential.

TB-500 promotes a process called angiogenesis. It helps stimulate the growth of new capillaries from existing blood vessels, which improves blood flow to damaged tissues, delivering more oxygen and nutrients to accelerate the healing process.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Quick Dosing Reference · research convention, not a validated dose

4 100 0.1mg 10 250 0.25mg 20 500 0.5mg 750 0.75mg 40 1000 1mg
STORAGE

Storage Requirements

Lyophilized (powder) Room temperature or refrigerated, protect from light Reconstituted Refrigerated 36-46F (2-8C), use within 30 days
02

Question drills

Open a question for its connected answer.

01What If Dosing Frequency Is Reduced From Twice Weekly to Once Weekly After Week 8?+

Reducing dose frequency after week 8 slows but doesn't completely halt the remodeling process. Provided the initial angiogenic phase completed successfully. Studies using tapering protocols (twice weekly for 8 weeks, then once weekly for 8–12 weeks) show intermediate outcomes: scar reduction reaches 20–28% instead of 35–45%, and relapse rates increase to 25–35% instead of 8–12%. This approach may be viable in cost-constrained research settings, but it sacrifices peak efficacy for reduced peptide consumption.

SOURCE / realpeptides.co ↗
02What If TB-500 Is Administered More Than 96 Hours After Surgery?+

Administer it anyway. Delayed administration still provides benefit, though the magnitude is reduced. Peak inflammatory cytokine expression occurs within the first 72 hours post-surgery, and TB-500's anti-inflammatory modulation is most impactful during that window. Beyond 96 hours, the wound enters the proliferative phase where collagen deposition dominates, and TB-500's actin-regulatory effects contribute less to overall healing velocity. Studies show 15–20% improvement in wound tensile strength even with delayed administration, compared to 30–40% when initiated early.

SOURCE / realpeptides.co ↗
03What If I Want to Use TB-500 Alongside BPC-157 for a Specific Tendon Injury?+

Combining TB-500 and BPC-157 is mechanistically sound. TB-500 provides systemic actin regulation and angiogenesis, while BPC-157 delivers localized VEGF modulation and collagen synthesis support. A common protocol: TB-500 at 2–5mg twice weekly systemically, BPC-157 at 250–500mcg daily injected near the injury site. There are no documented contraindications or adverse interactions between the two peptides in veterinary or preclinical contexts. Some athletes report faster tendon healing timelines when combining both peptides during the acute injury phase (first 4–6 weeks) compared to using either peptide alone.

SOURCE / realpeptides.co ↗
04What If I Miss a Scheduled TB-500 Injection?+

If you miss a twice-weekly dose by fewer than 3 days, administer it as soon as you remember and resume your regular schedule. If more than 3 days have passed, skip the missed dose entirely and continue on your next scheduled date. Do not double-dose to compensate. TB-500's half-life is approximately 10 hours, meaning plasma levels decline rapidly, but the downstream effects (actin mobilization, angiogenesis) persist for 4–6 days after administration.

SOURCE / realpeptides.co ↗
05What If I Don't See Improvement After Four Weeks of TB-500?+

First, confirm you're using a legitimate product with third-party purity testing. Underdosed or degraded peptides are common in the research peptide market. Second, reassess your training load: if you're still doing 80% of your previous volume, the peptide can't compensate for insufficient rest. Third, check your injection technique. Subcutaneous administration should be consistent, and the reconstituted solution must be refrigerated between uses. If all variables are controlled and you see zero improvement after six weeks, the issue may be biomechanical (overpronation, hip weakness, improper footwear) rather than purely tissue-level healing.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

What Is TB-500? Complete Research-Use-Only Guide

What Is TB-500? A Complete Research-Use-Only Guide TB-500 is a synthetic peptide related to an active region of thymosin beta-4, studied in laboratory and animal-model research. A complete research-use-only guide. Research-use-only context. This is a molecular-biology overview of TB-500 and its parent peptide thymosin beta-4 (Tβ4), based on published in vitro and pre-clinical literature. It is not a dosing guide, not an efficacy claim, not medical advice, and not a recommendation for human or animal use. American Peptides supplies TB-500 for in vitro research only. TB-500 is a synthetic peptide based on thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-sequestering protein (~4,963 Da) first identified in calf thymus and later shown to be the dominant G-actin-binding peptide in most mammalian cells (Safer, Elzinga & Nachmias, 1991). In the research literature, "TB-500" most commonly refers not to the full Tβ4 protein but to a short, N-terminally acetylated synthetic fragment corresponding to residues 17–23 of Tβ4 — the sequence Ac-LKKTETQ — which contains the actin-binding motif (Ho et al., 2012; Esposito et al., 2012). Some research-peptide suppliers also use the "TB-500" label for full-length synthetic Tβ4; always verify the sequence on the Certificate of Analysis. Below is the molecular-biology breakdown for working researchers — strictly receptor- and pathway-level pharmacology, no outcome claims. What TB-500 actually is at the molecular level The confusion around TB-500 starts at nomenclature, so it helps to separate three related entities: Thymosin beta-4 (Tβ4) 43 amino acids (full sequence beginning SDKPDMAEI…) ~4,963 Da The endogenous protein. Dominant intracellular G-actin-sequestering peptide. TB-500 (research-peptide label) Most commonly the N-terminally acetylated 17–23 fragment, Ac-LKKTETQ (7 aa) ~889 Da (Ac-LKKTETQ-OH) A synthetic fragment encompassing Tβ4’s actin-binding motif. Characterized in doping-control literature (Esposito et al., 2012). AC-SDKP Ac-Ser-Asp-Lys-Pro (residues 1–4 of Tβ4) ~487 Da A separate N-terminal tetrapeptide cleaved from Tβ4 in vivo by prolyl oligopeptidase. Studied independently as an angiogenic / anti-fibrotic factor (Wang et al., 2004). Conflating these three molecules is one of the most common errors in the secondary literature. Tβ4 is the full protein, TB-500 is most often a short actin-binding fragment of it, and AC-SDKP is a different short fragment with its own pharmacology. All three are studied in different assay systems with different readouts. The actin-sequestering mechanism Tβ4’s defining biochemical activity was established by Safer, Elzinga and Nachmias in 1991, who showed that the previously characterized actin-sequestering peptide "Fx" was sequence-identical to Tβ4 and forms a 1:1 complex with G-actin monomers, inhibiting their polymerization into F-actin filaments (Safer, Elzinga & Nachmias, 1991). Later mutational mapping localized the critical actin-binding contacts to the central helical region of Tβ4, with the 17-LKKTETQ-23 motif identified as essential for the actin interaction (Van Troys et al., 1996). Biophysical studies confirmed that Tβ4 binding measurably changes the conformation and dynamics of the actin monomer itself (De La Cruz et al., 2000). This is the molecular rationale for the "TB-500" design: synthesizing the 17–23 actin-binding motif as a stand-alone short peptide allows researchers to study an actin-interaction signal independent of the rest of the Tβ4 sequence, in a molecule that is far simpler to synthesize, characterize, and quantify by mass spectrometry. Tβ10 was subsequently shown to share the same monomer-sequestering function, establishing β-thymosins as a family of actin regulators (Yu et al., 1993). Wound-healing and migration pathways studied in animal models Beyond pure actin biochemistry, Tβ4 has been studied in a range of injury and migration models. In the Goldstein-lab program at George Washington University, Tβ4 was reported to accelerate corneal re-epithelialization and reduce inflammatory infiltrate after alkali injury in mice, with several inflammatory chemokines reduced several-fold in treated corneas versus controls (Sosne et al., 2002). That program later progressed to clinical research on Tβ4 eyedrops for dry eye and neurotrophic keratopathy (Sosne, 2018). In a separate landmark paper, Bock-Marquette and colleagues reported in Nature that Tβ4 forms a complex with PINCH and integrin-linked kinase (ILK), activating Akt and promoting cardiomyocyte and endothelial-cell migration and survival in a mouse coronary-ligation model (Bock-Marquette et al., 2004). The broader regenerative biology of Tβ4 across dermatology, ophthalmology, and cardiology was synthesized in a 2012 review from the Goldstein, Hannappel, Sosne and Kleinman labs (Goldstein et al., 2012). AC-SDKP: the separate N-terminal tetrapeptide Tβ4 is also a substrate for prolyl oligopeptidase, which liberates the N-terminal tetrapeptide AC-SDKP (Ac-Ser-Asp-Lys-Pro). AC-SDKP is then degraded by angiotensin-converting enzyme (ACE) — the same enzyme targeted by cardiovascular ACE inhibitors — which is one reason it has received independent attention. In published animal and in vitro studies, AC-SDKP stimulates endothelial-cell proliferation, migration, and tube formation in a dose-dependent manner and increases capillary density after myocardial infarction in rodent models (Wang et al., 2004). It is mechanistically distinct from the LKKTETQ-style "TB-500" fragment: AC-SDKP signals via angiogenic / anti-fibrotic pathways rather than through direct G-actin binding. Comparative peptides table TB-500 (Ac-LKKTETQ) 17–23 actin-binding fragment of Tβ4 Actin sequestration, cell-migration assays Full Tβ4 (43 aa) Native peptide Wound healing, corneal repair, cardiac repair (Goldstein et al., 2012) Residues 1–4 of Tβ4, cleaved by prolyl oligopeptidase Angiogenesis, anti-fibrosis (Wang et al., 2004) BPC-157 Unrelated; gastric-juice-derived peptide Often studied alongside TB-500 in pre-clinical tissue-repair literature Why purity and sequence verification matter Because "TB-500" is a label rather than a single defined sequence in commerce, batch-specific verification is non-negotiable for a working researcher. The minimum questions a Certificate of Analysis (COA) should answer: What is the actual sequence in this vial? Ac-LKKTETQ-OH (the 7-aa fragment), full 43-aa Tβ4, or something else entirely? Mass-spectrometry data should match the claimed sequence within typical instrument tolerance. What is the HPLC purity? Common synthesis impurities at this length include deletion sequences and incomplete acetylation; both shift the apparent pharmacology in actin-binding assays. Does the lot number on the vial match the lot number on the COA? Lot mismatch is a frequent source of irreproducibility in peptide research. Every TB-500 lot we ship has independent third-party HPLC and mass-spectrometry verification at ≥99% purity. See current COAs. Laboratory handling TB-500 is supplied lyophilized for stability. Reconstitution, storage temperature, light exposure, and freeze-thaw cycle count all measurably affect short-peptide integrity in published stability work. Researchers should keep reconstituted stocks cold and protected from light, minimize freeze-thaw cycles, and maintain lot traceability against the COA. This is bench-chemistry guidance for in vitro research only — it is not administration guidance, and TB-500 is not a drug, supplement, food, or medical product. Frequently Asked Questions What is the difference between TB-500 and full thymosin beta-4? Thymosin beta-4 (Tβ4) is the full 43-amino-acid endogenous protein (~4,963 Da), first identified as the dominant G-actin-sequestering peptide in mammalian cells (Safer, Elzinga & Nachmias, 1991). "TB-500" is a research-peptide label most commonly applied to a short, N-terminally acetylated synthetic fragment, Ac-LKKTETQ, corresponding to residues 17–23 of Tβ4 — the region carrying the actin-binding motif characterized by mutational mapping (Van Troys et al., 1996; Esposito et al., 2012). Some suppliers use the "TB-500" label for full-length synthetic Tβ4; verify against the lot COA. How does TB-500 relate to actin? The 17–23 LKKTETQ region of Tβ4 makes the critical contacts with G-actin monomers; deletions or mutations in this region abolish the actin interaction in published mutational studies (Van Troys et al., 1996). The parent Tβ4 protein forms a 1:1 complex with G-actin and prevents its polymerization into F-actin filaments (Safer, Elzinga & Nachmias, 1991), and Tβ4 binding measurably alters monomer conformation and dynamics (De La Cruz et al., 2000). The TB-500 fragment is studied as an isolated probe of this actin-binding motif. Why is TB-500 studied alongside BPC-157? The two peptides are sequence- and origin-unrelated — TB-500 is a Tβ4 fragment, BPC-157 is a synthetic peptide derived from a gastric-juice protein — but they are frequently paired in pre-clinical tissue-repair literature because they engage different mechanisms of interest in injury models. TB-500’s research context centers on actin-sequestering and cell-migration pathways (Safer, Elzinga & Nachmias, 1991); BPC-157’s pre-clinical literature emphasizes nitric-oxide and growth-factor signaling. Researchers designing comparator studies should be explicit that these are distinct pathways studied in distinct assay systems — not interchangeable molecules. What is AC-SDKP and is it the same as TB-500? No. AC-SDKP (Ac-Ser-Asp-Lys-Pro) is the N-terminal tetrapeptide cleaved from Tβ4 by prolyl oligopeptidase — residues 1–4 of the parent protein — and is studied for angiogenic and anti-fibrotic activity in endothelial and cardiac models (Wang et al., 2004). TB-500, as most commonly characterized in the analytical-chemistry literature, is the 17–23 actin-binding fragment Ac-LKKTETQ (Esposito et al., 2012). Different residues, different mechanism, different pharmacology. Is TB-500 approved for human or veterinary use? No. TB-500 is not approved as a drug, supplement, food, or medical product in any jurisdiction we are aware of, and it is prohibited in equine sport — the analytical-chemistry literature on TB-500 detection was developed largely for veterinary doping control (Ho et al., 2012). American Peptides supplies TB-500 strictly for in vitro laboratory research. What molecular weight should I expect on the COA? If the lot is the standard Ac-LKKTETQ-OH fragment, the monoisotopic / average mass should be near ~889 Da. If the lot is full-length synthetic Tβ4 (43 aa), the mass should be near ~4,963 Da. If your COA does not match either, the material is not what is conventionally labeled TB-500 — do not proceed without sequence clarification from the supplier. How should TB-500 be handled in the lab? Store lyophilized at −20 °C or colder. Reconstitute in an appropriate aqueous buffer immediately before use, keep reconstituted stocks cold and protected from light, aliquot to minimize freeze-thaw cycles, and maintain lot-number traceability against the COA. This is bench-chemistry handling guidance only — not administration guidance. Citations Safer D., Elzinga M., Nachmias V.T. "Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable." J Biol Chem. 1991;266(7):4029–4032. PubMed. Yu F.X., Lin S.C., Morrison-Bogorad M., Atkinson M.A., Yin H.L. "Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins." J Biol Chem. 1993;268(1):502–509. PubMed. Van Troys M., Dewitte D., Goethals M., Carlier M.F., Vandekerckhove J., Ampe C. "The actin binding site of thymosin beta 4 mapped by mutational analysis." EMBO J. 1996;15(2):201–210. PubMed. De La Cruz E.M., Ostap E.M., Brundage R.A., Reddy K.S., Sweeney H.L., Safer D. "Thymosin-beta(4) changes the conformation and dynamics of actin monomers." Biophys J. 2000;78(5):2516–2527. PubMed. Sosne G., Szliter E.A., Barrett R., Kernacki K.A., Kleinman H., Hazlett L.D. "Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury." Exp Eye Res. 2002;74(2):293–299. PubMed. Wang D., Carretero O.A., Yang X.Y., Rhaleb N.E., Liu Y.H., Liao T.D., Yang X.P. "N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo." Am J Physiol Heart Circ Physiol. 2004;287(5):H2099–H2105. PubMed. Bock-Marquette I., Saxena A., White M.D., Dimaio J.M., Srivastava D. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466–472. PubMed. Goldstein A.L., Hannappel E., Sosne G., Kleinman H.K. "Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications." Expert Opin Biol Ther. 2012;12(1):37–51. PubMed. Esposito S., Deventer K., Goeman J., Van der Eycken J., Van Eenoo P. "Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential." Drug Test Anal. 2012;4(9):733–738. PubMed. Ho E.N., Kwok W.H., Lau M.Y., Wong A.S., Wan T.S., Lam K.K., Schiff P.J., Stewart B.D. "Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry." J Chromatogr A. 2012;1265:57–69. PubMed. Sosne G. "Thymosin beta 4 and the eye: the journey from bench to bedside." Expert Opin Biol Ther. 2018;18(sup1):99–104. PubMed. This article is for laboratory research reference only. American Peptides products are sold strictly for in vitro research. Not for human or animal consumption, not a drug, not a supplement, not a medical product. Last reviewed: 2026-05-25 by American Peptides Research Team.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

4. Thymosin Beta-4 vs TB-500

This is one of the most common questions in peptide research. TB-500 is not the same peptide as Thymosin Beta-4, though they are closely related.

Continue reading

Related articles